Table 2. Country-specific distribution of OAC and antiplatelet therapies.
| Total | Albania | B&H | Bulgaria | Croatia | Montenegro | Romania | Serbia | |
|---|---|---|---|---|---|---|---|---|
| n = 2663 | n = 313 | n = 265 | n = 443 | n = 159 | n = 102 | n = 699 | n = 682 | |
| No antithrombotic therapy (%) | 264 (9.9) | 23 (7.3) | 28 (10.6) | 46 (10.4) | 15 (9.4) | 11 (10.8) | 67 (9.6) | 74 (10.9) |
| Oral anticoagulant therapy-overall (%) | 1960 (73.6) | 229 (73.2) | 133 (50.2) | 319 (72.0) | 134 (84.3) | 72 (70.6) | 534 (76.4) | 539 (79.0) |
| VKAs (%) | 1662 (60.9) | 205 (65.5) | 111 (41.9) | 191 (43.1) | 110 (69.2) | 68 (66.7) | 482 (69.0) | 455 (66.7) |
| NOACs (%) | 338 (12.7) | 24 (7.7) | 22 (8.3) | 128 (28.9) | 24 (15.1) | 4 (3.9) | 52 (7.4) | 84 (12.3) |
| Oral anticoagulant therapy alone (%) | 1637 (61.5) | 162 (51.8) | 124 (46.8) | 286 (64.6) | 121 (76.1) | 50 (49.0) | 446 (63.8) | 448 (65.7) |
| Antiplatelet therapy (%) | 762 (28.6) | 128 (40.9) | 113 (42.6) | 111 (25.1) | 23 (14.5) | 41 (40.2) | 186 (26.6) | 160 (23.5) |
| Single antiplatelet drug only (%) | 320 (12.0) | 39 (12.5) | 88 (33.2) | 54 (12.2) | 9 (5.7) | 14 (13.7) | 61 (8.7) | 55 (8.1) |
| DAPT only (%) | 119 (4.5) | 22 (7.0) | 16 (6.0) | 24 (5.4) | 1 (0.6) | 5 (4.9) | 37 (5.3) | 14 (2.1) |
| Dual therapya | 240 (9.0) | 51 (16.3) | 9 (3.4) | 17 (3.8) | 9 (5.7) | 14 (13.7) | 74 (10.6) | 66 (9.7) |
| Triple therapyb | 83 (3.1) | 16 (5.1) | 0 (0.0) | 16 (3.6) | 4 (2.5) | 8 (7.8) | 14 (2.0) | 25 (3.7) |
B&H: Bosnia & Herzegovina; OAC: oral anticoagulant; VKA: vitamin-K antagonist; NOAC: non-vitamin K antagonist; DAPT: dual antiplatelet therapy.
aDual therapy: OAC plus single antiplatelet agent.
bTriple therapy: OAC plus dual antiplatelet therapy.